More Stories

Informist, Friday, Aug. 14, 2026

 

Please click here to read all liners published on this story

--Natco Pharma Apr-Jun consol net profit INR 2.07 bln 
--Natco Pharma Apr-Jun consol revenue INR 7.35 bln 
--Natco Pharma Apr-Jun consol PAT INR 2.07 bln vs INR 4.81 bln year ago 
--Natco Pharma Apr-Jun consol revenue INR 7.35 bln vs INR 13.29 bln yr ago 
--Natco Pharma to pay INR 1.50 per share interim dividend 
--Natco Pharma interim dividend record date is Aug 20
--Natco Pharma to raise up to INR 20 bln via equity 
--Natco Pharma Q1 consol pharmaceuticals sales INR 6.94 bln vs INR 12.94 bln

 

By Rosalin Lenka 

 

MUMBAI – Natco Pharma Ltd. reported a sharp decline in consolidated net profit for the June quarter mainly due to a steep fall in revenue from operations. The company's total expenses also declined, but at a slower pace than revenue.

 

The drugmaker reported a consolidated net profit of INR 2.07 billion for the June quarter, down 57% from INR 4.81 billion a year ago. Revenue from operations for the quarter fell 45% on year to INR 7.35 billion from INR 13.29 billion.

 

Total expenses fell 26% on year to INR 6.09 billion from INR 8.19 billion. Cost of materials consumed declined 13% on year to INR 1.58 billion, while employee benefits expense rose 6% on year to INR 1.79 billion. Finance costs rose sharply to INR 130 million from INR 32 million. Other expenses fell 38% on year to INR 2.22 billion.

The company will pay interim dividend of INR 1.50 per share. The record date for the dividend is Aug. 20.

 
At 1516 IST, shares of Natco Pharma traded at INR 906.35 apiece on the National Stock Exchange after the June quarter earnings were announced. The stock is down nearly 5% from Thursday.

 

In terms of segments, the company's revenue from the pharmaceutical business fell 46% on year to INR 6.94 billion, but revenue from agro chemicals grew 18% to INR 408 million. The company's earnings before interest, tax, depreciation, and amortisation for the June quarter stood at INR 2.46 billion, down 61% from INR 6.33 billion a year ago. The EBITDA margin contracted significantly to 30.9% from 45.5% in the year-ago quarter. 

 

On Friday, shares of Natco Pharma ended 5.1% lower at INR 903.15 apiece on the National Stock Exchange. The company announced its June quarter earnings after market hours.  End

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.